IL137871A0 - Self-regulated apoptosis of inflammatory cells by gene therapy - Google Patents
Self-regulated apoptosis of inflammatory cells by gene therapyInfo
- Publication number
- IL137871A0 IL137871A0 IL13787199A IL13787199A IL137871A0 IL 137871 A0 IL137871 A0 IL 137871A0 IL 13787199 A IL13787199 A IL 13787199A IL 13787199 A IL13787199 A IL 13787199A IL 137871 A0 IL137871 A0 IL 137871A0
- Authority
- IL
- Israel
- Prior art keywords
- self
- gene therapy
- inflammatory cells
- regulated apoptosis
- apoptosis
- Prior art date
Links
- 238000001415 gene therapy Methods 0.000 title 1
- 230000007820 inflammatory cell apoptotic process Effects 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7631698P | 1998-02-27 | 1998-02-27 | |
| PCT/US1999/000637 WO1999043840A1 (en) | 1998-02-27 | 1999-01-12 | Self-regulated apoptosis of inflammatory cells by gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL137871A0 true IL137871A0 (en) | 2001-10-31 |
Family
ID=22131220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13787199A IL137871A0 (en) | 1998-02-27 | 1999-01-12 | Self-regulated apoptosis of inflammatory cells by gene therapy |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6537784B1 (xx) |
| EP (1) | EP1056877A1 (xx) |
| JP (1) | JP2002504381A (xx) |
| KR (1) | KR20010086587A (xx) |
| CN (1) | CN1292032A (xx) |
| AR (1) | AR014661A1 (xx) |
| AU (1) | AU761497B2 (xx) |
| BR (1) | BR9909250A (xx) |
| CA (1) | CA2321178A1 (xx) |
| CO (1) | CO4820446A1 (xx) |
| HU (1) | HUP0100776A3 (xx) |
| IL (1) | IL137871A0 (xx) |
| NZ (1) | NZ506941A (xx) |
| PE (1) | PE20000335A1 (xx) |
| PL (1) | PL343248A1 (xx) |
| TR (1) | TR200002496T2 (xx) |
| WO (1) | WO1999043840A1 (xx) |
| ZA (1) | ZA991519B (xx) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040039186A1 (en) * | 1997-02-28 | 2004-02-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Self-regulated apoptosis of inflammatory cells by gene therapy |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| CN1555268B (zh) | 2001-07-17 | 2013-04-03 | 研究发展基金会 | 含促调亡蛋白质的治疗剂 |
| US6867237B1 (en) * | 2001-07-23 | 2005-03-15 | Senesco Technologies, Inc. | DNA encoding apoptosis-induced eucaryotic initiation factor-5A and deoxyhypusine synthase and a method for controlling apoptosis in animals and humans |
| EP1537204B1 (en) * | 2002-08-23 | 2010-02-10 | Gabriele Prof. Dr. Multhoff | Granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells |
| WO2004028342A2 (en) * | 2002-09-25 | 2004-04-08 | Board Of Regents, The University Of Texas System | Endogenous granzyme b in human non-hematopoietic cells |
| ES2611608T3 (es) * | 2005-10-21 | 2017-05-09 | Catalyst Biosciences, Inc. | Proteasas modificadas que inhiben la activación del complemento |
| BRPI0817233A2 (pt) * | 2007-09-28 | 2012-11-06 | Intrexon Corp | construções terapêuticas de gene de trca e bireatores para a expressão de moléculas bioterapêuticas, e usos das mesmas |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01137976A (ja) * | 1987-11-20 | 1989-05-30 | Asahi Chem Ind Co Ltd | 新規dnaフラグメント |
| US5792751A (en) | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
| EP0653943A4 (en) * | 1992-07-13 | 1996-10-02 | Baylor College Medicine | A SOMATIC GENE THERAPY TARGETING JOINTS. |
| IL107250A (en) * | 1993-10-12 | 2001-08-08 | Yeda Res & Dev | Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins |
| US5744304A (en) | 1995-05-30 | 1998-04-28 | Board Of Regents, The University Of Texas System | Inflammation-induced expression of a recombinant gene |
| US6004942A (en) | 1995-08-30 | 1999-12-21 | The Regents Of The University Of California | Methods for treating arthritis by administering an apoptosis regulator |
| US6525184B1 (en) * | 1997-02-28 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Self-regulated apoptosis of inflammatory cells |
-
1999
- 1999-01-12 NZ NZ506941A patent/NZ506941A/en unknown
- 1999-01-12 BR BR9909250-6A patent/BR9909250A/pt not_active IP Right Cessation
- 1999-01-12 WO PCT/US1999/000637 patent/WO1999043840A1/en not_active Application Discontinuation
- 1999-01-12 IL IL13787199A patent/IL137871A0/xx unknown
- 1999-01-12 HU HU0100776A patent/HUP0100776A3/hu unknown
- 1999-01-12 PL PL99343248A patent/PL343248A1/xx unknown
- 1999-01-12 CA CA002321178A patent/CA2321178A1/en not_active Abandoned
- 1999-01-12 TR TR2000/02496T patent/TR200002496T2/xx unknown
- 1999-01-12 CN CN99803317A patent/CN1292032A/zh active Pending
- 1999-01-12 JP JP2000533579A patent/JP2002504381A/ja active Pending
- 1999-01-12 EP EP99901438A patent/EP1056877A1/en not_active Withdrawn
- 1999-01-12 KR KR1020007009326A patent/KR20010086587A/ko not_active Withdrawn
- 1999-01-12 US US09/229,151 patent/US6537784B1/en not_active Expired - Lifetime
- 1999-01-12 AU AU21132/99A patent/AU761497B2/en not_active Ceased
- 1999-02-24 CO CO99011570A patent/CO4820446A1/es unknown
- 1999-02-25 ZA ZA9901519A patent/ZA991519B/xx unknown
- 1999-02-25 PE PE1999000161A patent/PE20000335A1/es not_active Application Discontinuation
- 1999-02-26 AR ARP990100832A patent/AR014661A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR014661A1 (es) | 2001-03-28 |
| CO4820446A1 (es) | 1999-07-28 |
| AU761497B2 (en) | 2003-06-05 |
| CA2321178A1 (en) | 1999-09-02 |
| CN1292032A (zh) | 2001-04-18 |
| HUP0100776A3 (en) | 2003-08-28 |
| HUP0100776A2 (hu) | 2001-06-28 |
| ZA991519B (en) | 1999-11-23 |
| TR200002496T2 (tr) | 2000-11-21 |
| KR20010086587A (ko) | 2001-09-13 |
| BR9909250A (pt) | 2001-09-04 |
| JP2002504381A (ja) | 2002-02-12 |
| AU2113299A (en) | 1999-09-15 |
| PL343248A1 (en) | 2001-07-30 |
| NZ506941A (en) | 2004-01-30 |
| WO1999043840A1 (en) | 1999-09-02 |
| EP1056877A1 (en) | 2000-12-06 |
| PE20000335A1 (es) | 2000-04-26 |
| US6537784B1 (en) | 2003-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0002317A3 (en) | Self-regulated apoptosis of inflammatory cells by gene therapy | |
| NO992704D0 (no) | Serum-fritt celledyrkningsmedium | |
| HUP0104046A3 (en) | Adenovirus-mediated gene therapy | |
| SG90108A1 (en) | Control of multiple equivalent functional units for power reduction | |
| IL138247A0 (en) | Substituted bisindolymaleimides for the inhibition of cell proliferation | |
| IL137871A0 (en) | Self-regulated apoptosis of inflammatory cells by gene therapy | |
| HUP0103252A3 (en) | Gene therapy method | |
| AU2001256555A1 (en) | New inhibotor of apoptosis of nerve cells | |
| GB9821921D0 (en) | Power cell | |
| GB9924981D0 (en) | Gene therapy | |
| EP0948254A4 (en) | CELLULAR REGULATION USED TO CONFIRM ENZYMATIC ACTIVITY | |
| AU1248899A (en) | Electrolytic cell for the production of fluorine | |
| IL150128A0 (en) | Substituted bisindolymaleimides for the inhibition of cell proliferation | |
| GB0406539D0 (en) | Gene therapy | |
| AU2892199A (en) | Cell cycle regulated genes | |
| AU6823000A (en) | Methods for determining the proliferation activity of cells | |
| GB9803214D0 (en) | Micro-injection of cells | |
| GB9820930D0 (en) | Micro-injection of cells | |
| TW390551U (en) | Structure of enclosure assembly for power supply | |
| IL147594A0 (en) | Methods of inducing cell death | |
| AU3899399A (en) | Methods of inducing apoptosis in a cell | |
| ZA9811600B (en) | SAG: sensitive to apoptosis gene | |
| AU2002344717A1 (en) | Method of inducing apoptosis in cancer cells | |
| SI1064279T1 (en) | Substituted bisindolylmaleimides for the inhibition of cell proliferation | |
| TW365471U (en) | Power connector of separate type |